Lilovon

Acetylcysteine, the active ingredient in Lilovon, is a mucolytic agent presented as an oral dosage form for oral use. It reduces the viscosity of respiratory secretions and is employed in the management of acute and chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, and other upper respiratory tract infections characterized by thick mucus.

GNH USA supplies Lilovon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory requirements and is manufactured under GMP conditions.

Lilovon (acetylcysteine) acts as a mucolytic and expectorant, facilitating clearance of thick respiratory secretions. Acute bronchitis: improves mucus clearance and eases cough in patients with acute inflammation of the bronchial tubes. Chronic bronchitis: reduces sputum viscosity, helping long‑term management of chronic mucus hypersecretion. Chronic obstructive pulmonary disease (COPD): aids airway patency by thinning secretions during exacerbations. Cystic fibrosis: assists in the removal of thick, sticky mucus from the airways, supporting respiratory therapy.

Acetylcysteine is generally well tolerated, but oral administration can be associated with several adverse reactions. Common Side Effects: - Nausea: mild stomach upset that may be transient after taking the medication. - Diarrhea: loose stools or increased frequency of bowel movements, usually self‑limiting. - Headache: transient mild headache that often resolves without intervention. Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction presenting with rash, facial swelling, wheezing, or difficulty breathing and requires immediate medical attention. - Stevens‑Johnson syndrome: rare, potentially life‑threatening skin blistering and mucosal involvement that mandates urgent care. - Hepatotoxicity: elevation of liver enzymes or jaundice indicating possible liver stress, warranting laboratory monitoring.

When using Lilovon, certain precautions should be observed to minimize risk and ensure optimal effectiveness. - Pregnancy: safety has not been established; use only if potential benefit outweighs risk. - Breastfeeding: limited data; consider discontinuation if infant shows adverse effects. - Asthma: monitor for bronchospasm, especially in patients with reactive airway disease. - G6PD deficiency: avoid use due to risk of hemolysis. - Concomitant mucolytics: assess cumulative effect on mucus clearance. - Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Acetylcysteine can interact with several medicines; awareness of these interactions helps avoid reduced efficacy or increased toxicity. Major Interactions (Avoid): - Nitroprusside: acetylcysteine may potentiate hypotensive effects; concurrent use is contraindicated. - Activated charcoal: may bind acetylcysteine and reduce its absorption if given within 2 hours. Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): acetylcysteine may enhance anticoagulant effect; monitor INR. - Antibiotics (e.g., carbapenems): potential for altered plasma levels; observe clinical response. - Bronchodilators: additive mucolytic effect may increase cough; adjust dosage if needed.